Johnson & Johnson announced on November 19, 2026 that Memorial Hermann-Texas Medical Center in Houston has become the first hospital in the United States to commercially install its OTTAVA Robotic Surgical System, marking the start of the platform's early-access commercial rollout. Memorial Hermann had already served as a clinical trial site for OTTAVA under the Investigational Device Exemption program that supported its regulatory authorization, according to Johnson & Johnson.
What makes OTTAVA's design different from other surgical robots?
OTTAVA integrates four robotic arms directly into a standard-sized surgical table rather than mounting them on a separate cart or tower wheeled in next to a conventional table, which J&J describes as the first FDA-authorized design of its kind. The table-integrated approach is meant to help hospitals expand operating room capacity and streamline workflows, since staff can convert a room between open and robotic procedures without swapping equipment in and out. The system also connects to J&J's Polyphonic Digital Ecosystem, the company's platform for linking surgical data and devices across procedures.
What can OTTAVA actually be used for right now?
The FDA granted OTTAVA De Novo authorization in July 2026 covering 10 general surgery procedures in the upper abdomen, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. That is a narrower initial scope than Intuitive's long-established da Vinci platform, but it overlaps heavily with Medtronic's Hugo system, which won its own general surgery clearance covering similar upper-abdomen procedures. "Today's milestone is a significant step... as we commercialize OTTAVA," said Tim Schmid, J&J MedTech's executive vice president.
Why is the robotic surgery market getting more crowded right now?
Intuitive's da Vinci has dominated the general surgery robotics market for two decades, but 2026 has seen Medtronic's Hugo, J&J's OTTAVA and other platforms all push into overlapping general surgery indications within months of each other, each chasing a market that analysts estimate covers roughly 3.5 million U.S. surgeries a year. Hospitals like Memorial Hermann that run multiple robotic brands, rather than standardizing on one, are becoming more common as systems compete on specific strengths: OTTAVA on table-integrated design, Hugo on modularity, da Vinci on surgeon familiarity and installed base. "OTTAVA is designed around real-world challenges facing hospitals," said Hani Abouhalka, who chairs J&J's Surgery Company Group.
What comes after this first installation?
J&J described the Memorial Hermann installation as the start of a "selective" U.S. customer launch, meaning the company plans to expand gradually rather than ship OTTAVA broadly right away, while it gathers early feedback and evaluates additional surgical indications beyond the 10 already cleared. Dr. Erik Wilson, who chairs Memorial Hermann's minimally invasive surgery division, framed the installation as a continuation of the hospital's role in OTTAVA's clinical trials rather than a one-off purchase. Expect J&J to name additional launch hospitals over the coming months, with pricing and installation volumes likely to stay undisclosed given how early the rollout remains.